Citations

Clear

6273 citation(s) found for "To, Andrew".

Antibody Prevalence in Epilepsy and Encephalopathy score: Increased specificity and applicability
Dubey, Divyanshu , Pittock, Sean J. , McKeon, Andrew , Pittock, S J , McKeon, Andrew , Dubey, Divyanshu

Mayo Clinic

Epilepsia | February 6, 2019 | Volume: 60 | Issue: 2 | Pages: 367-369

10.1111/epi.14649 | PMID 30727035 Get It

Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis
Lapumnuaypol, Kamolyut , Tiu, Andrew , Thongprayoon, Charat , Wijarnpreecha, Karn , Ungprasert, Patompong , Cheungpasitporn, Wisit , Cheungpasitporn, Wisit , Thongprayoon, Charat , Wijarnpreecha, Karn , Mao, Michael A.

Mayo Clinic

QJM: An International Journal of Medicine | February 6, 2019 | Volume: 112 | Issue: 6 | Pages: 421-427

10.1093/qjmed/hcz039 | PMID 30753687 Get It

Autoimmune glial fibrillary acidic protein astrocytopathy
Kunchok, Amy , Ζεκερίδου, Αναστασία , McKeon, Andrew , Zekeridou, Anastasia, Pittock, Sean J , McKeon, Andrew

Mayo Clinic

Current Opinion in Neurology | February 6, 2019 | Volume: 32 | Issue: 3 | Pages: 452-458

10.1097/wco.0000000000000676 | PMID 30724768 Get It

Purpose of review To describe a recently characterized autoimmune, inflammatory central nervous system (CNS) disorder known as autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy. Recent findings Affected patients present with symptoms of one or more of meningitis (headache and neck ache), encephalitis (delirium, tremor, seizures, or psychiatric symptoms), and myelitis (sensory symptoms and weakness). Optic disc papillitis (blurred vision) is common. CNS inflammation is evident in characteristic T1 postgadolinium enhancement of GFAP-enriched CNS regions, and lymphocytic cerebrospinal fluid (CSF) white cell count elevation. CSF is more reliable than serum for GFAP-immunoglobulin G (IgG) testing. Ovarian teratoma commonly coexists, particularly among patients with accompanying N-methyl-D-aspartate receptor or aquaporin-4 autoimmunity. Parainfectious autoimmunity is suspected in some other patients, though the culprit organism is rarely verified. Pathophysiologic relevance of T cells is underscored by neuropathology and cases of dysregulated T-cell function (HIV or checkpoint inhibitor cancer therapy). Corticosteroid-responsiveness is a hallmark of the disease. Relapses occur in approximately 20% of patients, necessitating transition to a steroid-sparing drug. Reported outcomes vary, though in the authors’ experience, early and sustained intervention usually portends recovery. Summary Autoimmune GFAP astrocytopathy is a treatable autoimmune CNS disease diagnosable by GFAP-IgG testing in CSF. This disease presents opportunities to explore novel mechanisms of CNS autoimmunity and inflammation.
Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study
Bartlett, Nancy L. , Smith, Sonali M. , Leonard, John P. , Evens, Andrew M. , Friedberg, Jonathan W. , Bartlett, Nancy L , Evens, Andrew M , Hsi, Eric D. , Li, Hongli , Nixon, Andrew B. , Schöder, Heiko , LeBlanc, Michael , Kahl, Brad S. , Scott, David W. , Rimsza, Lisa M.

Mayo Clinic

Blood | February 6, 2019 | Volume: 133 | Issue: 16 | Pages: 1762-1765

10.1182/blood-2018-08-870915 | PMID 30723079 Get It

Abstract Serum soluble chemokines/cytokines produced by Hodgkin cells and the tumor microenvironment might be of value as biomarkers in classic Hodgkin lymphoma (cHL). We assessed serum thymus and activation-related chemokine (TARC), macrophage-derived chemokine (MDC), interleukin-10 (IL-10), and soluble CD163 (sCD163) levels at baseline, time of interim fluorodeoxyglucose positron emission tomography (PET), and after therapy in cHL patients treated on S0816, an intergroup phase 2 response-adapted study evaluating escalated therapy for interim PET (PET2)–positive patients (www.clinicaltrials.gov #NCT00822120). Epstein-Barr virus (EBV) status was assessed, and 559 serum samples were evaluated for TARC, MDC, IL-10, and sCD163 by immunoassay. EBV positivity correlated with higher sCD163 and IL-10 levels but lower TARC levels. While baseline biomarker levels were not associated with outcome, sCD163 levels at the time of PET2 were associated with favorable progression-free survival (PFS), adjusting for PET2 status. After therapy TARC, MDC, and IL-10 correlated with PFS and overall survival (OS) on univariable analysis, which remained significant adjusting for international prognostic score. When also adjusting for end-of-therapy PET results, TARC and IL-10 remained significantly associated with shorter PFS and OS. Exploratory analysis in PET2-negative patients showed that elevated posttherapy TARC and IL-10 levels were associated with PFS. Serum cytokine levels correlate with outcome in cHL and should be investigated further in risk-adapted cHL trials.
Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study
Mutsaerts, Henk , Mirza, Saira Saeed , Petr, Jan , Thomas, David L. , Cash, David M. , Bocchetta, Martina , Metcalfe, Arron W.S. , Shirzadi, Zahra , Robertson, Andrew D. , Tartaglia, Maria Carmela , Mitchell, Sara, Freedman, Morris , Tang‐Wai, David F. , Keren, Ron , Laforce, Robert , Tagliavini, Fabrizio , Borroni, Barbara , Galimberti, Daniela , Rowe, James B. , Graff, Caroline , Frisoni, Giovanni B. , Finger, Elizabeth , Sorbi, Sandro , Mendonça, Alexandre de , Rohrer, Jonathan D. , MacIntosh, Bradley J. , (GENFI), GENetic Frontotemporal dementia Initiative, Andersson, Christin, Archetti, Silvana, Arighi, Andrea , Benussi, Luisa , Binetti, Giuliano, Cosseddu, Maura , Dick, Katrina M., Fallström, Marie, Fenoglio, Chiara , Fumagalli, Giorgio, Gazzina, Stefano , Ghidoni, Roberta , Grisoli, Marina , Jelic, Vesna, Lombardi, Gemma, Maruta, Carolina, Mead, Simon , Meeter, Lieke , Minkelen, Rick van , Öijerstedt, Linn , Ourselin, Sébastien , Padovani, Alessandro , Panman, Jessica , Pievani, Michela, Polito, Cristina , Premi, Enrico, Prioni, Sara, Rademakers, Rosa, Redaelli, Veronica, Rossi, Giacomina , Thonberg, Håkan, Tiraboschi, Pietro , Verdelho, Ana, Warren, Jason D. , Binetti, Giuliano, Fallström, Marie, Fumagalli, Giorgio, Jelic, Vesna, Lombardi, Gemma, Maruta, Carolina, Pievani, Michela, Premi, Enrico, Prioni, Sara, Redaelli, Veronica, Verdelho, Ana, Binetti, Giuliano , Redaelli, Veronica , Prioni, Sara , Fumagalli, Giorgio , Frisoni, Giovanni B. , Finger, Elizabeth C. , Rowe, James B , Rohrer, Jonathan D , Padovani, Alessandro , Tartaglia, Maria Carmela , Cash, David M , Vita, Enrico De , Black, Sandra E. , Rogaeva, Ekaterina A. , Swieten, John C. van , Masellis, Mario , (GENFI), GENetic Frontotemporal dementia Initiative, Binetti, Giuliano, Fallström, Marie, Ferreira, Carlos , Fox, Nick C. , Fumagalli, Giorgio, Jelic, Vesna, Jiskoot, Lize C. , Lombardi, Gemma, Maruta, Carolina, Nacmias, Benedetta , Pievani, Michela, Premi, Enrico, Prioni, Sara, Rademakers, Rosa , Redaelli, Veronica, Rossor, Martin N. , Scarpini, Elio , Verdelho, Ana, Binetti, Giuliano, Fallström, Marie, Fumagalli, Giorgio, Jelic, Vesna, Lombardi, Gemma, Maruta, Carolina, Pievani, Michela, Premi, Enrico, Prioni, Sara, Redaelli, Veronica, Verdelho, Ana, Galimberti, Daniela , de Mendonça, Alexandre , Bocchetta, Martina , Tiraboschi, Pietro , Laforce, Robert , Graff, Caroline , Borroni, Barbara

Mayo Clinic

Brain | February 2, 2019 | Volume: 142 | Issue: 4 | Pages: 1108-1120

10.1093/brain/awz039 | PMID 30847466 Get It

Abstract Genetic forms of frontotemporal dementia are most commonly due to mutations in three genes, C9orf72, GRN or MAPT, with presymptomatic carriers from families representing those at risk. While cerebral blood flow shows differences between frontotemporal dementia and other forms of dementia, there is limited evidence of its utility in presymptomatic stages of frontotemporal dementia. This study aimed to delineate the cerebral blood flow signature of presymptomatic, genetic frontotemporal dementia using a voxel-based approach. In the multicentre GENetic Frontotemporal dementia Initiative (GENFI) study, we investigated cross-sectional differences in arterial spin labelling MRI-based cerebral blood flow between presymptomatic C9orf72, GRN or MAPT mutation carriers (n = 107) and non-carriers (n = 113), using general linear mixed-effects models and voxel-based analyses. Cerebral blood flow within regions of interest derived from this model was then explored to identify differences between individual gene carrier groups and to estimate a timeframe for the expression of these differences. The voxel-based analysis revealed a significant inverse association between cerebral blood flow and the expected age of symptom onset in carriers, but not non-carriers. Regions included the bilateral insulae/orbitofrontal cortices, anterior cingulate/paracingulate gyri, and inferior parietal cortices, as well as the left middle temporal gyrus. For all bilateral regions, associations were greater on the right side. After correction for partial volume effects in a region of interest analysis, the results were found to be largely driven by the C9orf72 genetic subgroup. These cerebral blood flow differences first appeared approximately 12.5 years before the expected symptom onset determined on an individual basis. Cerebral blood flow was lower in presymptomatic mutation carriers closer to and beyond their expected age of symptom onset in key frontotemporal dementia signature regions. These results suggest that arterial spin labelling MRI may be a promising non-invasive imaging biomarker for the presymptomatic stages of genetic frontotemporal dementia.
Uncommon Intraluminal Tumors of the Gallbladder and Biliary Tract: Spectrum of Imaging Appearances
Chatterjee, Argha , Vendrami, Camila Lopes , Bandy, Andrew , Menias, Christine O. , Hammond, Nancy A., Yaghmai, Vahid , Miller, Frank H. , Lopes Vendrami, Camila, Nikolaidis, Paul, Mittal, Pardeep K, Bandy, Andrew J, Yang, Guang-Yu, Miller, Frank H , Nikolaidis, Paul , Mittal, Pardeep Kumar , Yang, Guang‐Yu

Mayo Clinic

RadioGraphics | February 1, 2019 | Volume: 39 | Issue: 2 | Pages: 388-412

10.1148/rg.2019180164 | PMID 30707646 Get It

On-treatment changes of plasma protein biomarkers in CALGB/SWOG 80405 (Alliance).
Hatch, Ace J. , Starr, Mark D. , Brady, John C. , Innocenti, Federico , Lenz, Heinz‐Josef , Hurwitz, Herbert I. , Ou, Fang‐Shu , Zemla, Tyler , Liu, Yingmiao , Meyerhardt, Jeffrey A. , O’Reilly, Eileen M. , Venook, Alan P. , Nixon, Andrew B.

Mayo Clinic

Journal of Clinical Oncology | January 29, 2019 | Volume: 37 | Issue: 4_suppl | Pages: 588-588

10.1200/jco.2019.37.4_suppl.588 Get It

588 Background: CALGB/SWOG 80405 found no difference in overall survival (OS) or progression-free survival (PFS) in 1137 patients with KRAS wild-type metastatic colorectal cancer (mCRC) treated with either the anti-VEGF agent bevacizumab (Bev) or the anti-EGFR agent cetuximab (Cet) in combination with chemotherapy (FOLFOX or FOLFIRI) as first-line therapy. Additional molecular biomarkers are required for the optimization of treatment choices for patients with mCRC. Methods: Levels of 24 proteins were assayed in EDTA-plasma samples using multiplex ELISA techniques. Plasma samples were collected at baseline and cycle 2 day 1 (C2D1). Analyses of baseline markers have been presented previously. Changes from baseline to C2D1 were expressed as an L-ratio (LR, log2 of C2D1 divided by baseline measure). LRs dichotomized at 0 were analyzed for potential prognostic and predictive effects on OS and PFS using Cox models while adjusting for confounders (post-hoc optimized cutpoints were used for PLGF, TIMP1, VCAM1, and VEGFR3 due to skew in the distributions of these markers). P-values are not corrected for multiple testing. Results: Baseline and matched C2D1 samples from 446 patients (212 Bev/234 Cet) were available for analysis. Thirteen markers were differentially modulated between arms (p < 0.05). Early increases in CD73 (p = 0.001), ICAM1 (p = 0.022), TIMP1 (p = 0.001), TSP2 (p = 0.024), and VEGFR3 (p = 0.006) were prognostic for shorter OS. Increases in ICAM1 (p = 0.008), TIMP1 (p = 0.042), and TGFB1 (p = 0.039) were prognostic for shorter PFS. Changes in VEGFR3 (pint = 0.097) and TGFBR3 (pint = 0.052) were predictive for OS and PFS, respectively. No other markers were predictive for OS or PFS (p < 0.1). Conclusions: Changes in circulating plasma protein biomarkers observed in patients enrolled in CALGB/SWOG 80405 were both prognostic and predictive for OS and PFS and warrant further study. Such changes could provide valuable information and help guide treatment decisions. Support: U10CA180821, U10CA180882, U10CA180888, U10CA180830; ClinicalTrials.gov: NCT00265850. [Table: see text]
Common Ingredient Profiles of Multi-Ingredient Pre-Workout Supplements
Jagim, Andrew R. , Harty, Patrick S. , Camic, Clayton L., Jagim, Andrew R , Harty, Patrick S

Mayo Clinic

Nutrients | January 24, 2019 | Volume: 11 | Issue: 2 | Pages: 254

10.3390/nu11020254 | PMID 30678328 Get It

Multi-ingredient pre-workout supplements are a popular class of dietary supplements which are purported to improve exercise performance. However, the composition of these products varies substantially between formulations, thus making comparisons challenging. Therefore, the purpose of this study was to identify a common ingredient profile of top-selling pre-workout supplements and to compare ingredient dosages to established efficacious values. The top 100 commercially available pre-workout products were analyzed for listed ingredients and amounts, if available, from the supplement facts panel. The mean ± SD number of ingredients per supplement (n = 100) was 18.4 ± 9.7 with 8.1 ± 9.9 of these ingredients included in a proprietary blend at undisclosed quantities. Relative prevalence and average amounts of the top ingredients amounted to: Beta-alanine (87%; 2.0 ± 0.8 g), Caffeine (86%; 254.0 ± 79.5 mg), Citrulline (71%; 4.0 ± 2.5 g), Tyrosine (63%; 348.0 ± 305.7 mg), Taurine (51%; 1.3 ± 0.6 g), and Creatine (49%; 2.1 ± 1.0 g). Nearly half (44.3%) of all ingredients were included as part of a proprietary blend with undisclosed amounts of each ingredient. The average amount of beta-alanine per serving size was below the recommended efficacious dose. The average caffeine content was near the low end for an effective relative dose for a 70 kg individual (3–6 mg·kg−1 of bodyweight).